Format

Send to

Choose Destination
Anticancer Res. 2014 Aug;34(8):4589-93.

Case report: A breast cancer patient treated with GcMAF, sonodynamic therapy and hormone therapy.

Author information

1
Department of Life System, Institute of Technology and Science, Graduate School, The University of Tokushima, Tokushima, Japan Saisei Mirai Cell Processing Center, Osaka, Japan Kobe Saisei Mirai Clinic, Kobe, Japan Inui Immunotherapy Clinic, Osaka, Japan Tokyo Saisei Mirai Clinic, Tokyo, Japan contact@saisei-mirai.or.jp.
2
Kobe Saisei Mirai Clinic, Kobe, Japan.
3
Tokyo Saisei Mirai Clinic, Tokyo, Japan.
4
Department of Life System, Institute of Technology and Science, Graduate School, The University of Tokushima, Tokushima, Japan Saisei Mirai Cell Processing Center, Osaka, Japan.
5
Saisei Mirai Cell Processing Center, Osaka, Japan.
6
Inui Immunotherapy Clinic, Osaka, Japan.
7
Department of Life System, Institute of Technology and Science, Graduate School, The University of Tokushima, Tokushima, Japan.
8
Frontiers of Innovative Research in Science and Technology (FIRST), Konan University, Kobe, Japan Frontier Institute for Biomolecular Engineering Research (FIBER), Konan University, Kobe, Japan.
9
Division of Food and Drug Evaluation Science, Department of Community Medicine and Social Healthcare Science, Graduate School of Medicine, Kobe University, Kobe, Japan.

Erratum in

Abstract

Gc protein-derived macrophage-activating factor (GcMAF) occurs naturally in the human body. It has various functions, such as macrophage activation and antitumor activities. Recently, immunotherapy has become an attractive new strategy in the treatment of cancer. GcMAF-based immunotherapy can be combined with many other therapies. Sonodynamic therapy (SDT) using low-intensity ultrasound is a novel therapeutic modality. Ultrasound has been demonstrated to activate a number of sonosensitive agents allowing for the possibility of non-invasive targeted treatment for both superficial and deep-seated tumors. The current case study demonstrates that GcMAF and SDT can be used in combination with conventional therapies in patients with metastatic cancer, especially where treatment options are limited due to factors such as toxicity. This case study also suggests a new concept of cancer treatment using local destruction of cancer tissue, in this case conducted with SDT, to be used in combination with GcMAF immunotherapy as a systemic treatment.

KEYWORDS:

GeMAF; Immunotherapy; SDT; breast cancer; case report; macrophage; sonodynamic therapy

PMID:
25075104
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center